Previous Close | 181.00 |
Open | 182.40 |
Bid | 169.69 x 1300 |
Ask | 250.00 x 800 |
Day's Range | 176.50 - 192.61 |
52 Week Range | 66.01 - 249.42 |
Volume | 574,495 |
Avg. Volume | 433,570 |
Market Cap | 9.65B |
Beta (5Y Monthly) | 1.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.96 |
Earnings Date | May 05, 2021 - May 10, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 247.91 |
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.